Journal of Vascular Surgery
Volume 49, Issue 5 , Pages 1172-1180.e1 , May 2009

Metabolic syndrome: A predictor of adverse outcomes after carotid revascularization

Presented at the Peripheral Vascular Surgical Society Spring Meeting June, 2008, San Diego, Calif.

Received 13 July 2008 ,Accepted 3 December 2008.

References 

  1. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356–359
  2. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683–689
  3. Wallenfeldt K, Hulthe J, Fagerberg B. The metabolic syndrome in middle-aged men according to different definitions and related changes in carotid artery intima-media thickness (IMT) during 3 years of follow-up. J Intern Med. 2005;258:28–37
  4. Iannuzzi A, De Michele M, Bond MG, Sacchetti L, Fortunato G, Salvatore F, et al. Carotid artery remodeling in middle-aged women with the metabolic syndrome (from the “Progetto ATENA” study). Am J Cardiol. 2005;96:1162–1165
  5. Scuteri A, Najjar SS, Muller DC, Andres R, Hougaku H, Metter EJ, et al. Metabolic syndrome amplifies the age-associated increases in vascular thickness and stiffness. J Am Coll Cardiol. 2004;43:1388–1395
  6. Palomo I, Alarcón M, Moore-Carrasco R, Argilés JM. Hemostasis alterations in metabolic syndrome (review). Int J Mol Med. 2006;18:969–974
  7. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Bonadonna RC, et al. Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Bruneck study. Diabetes Care. 2003;26:1251–1257
  8. Anand SS, Yi Q, Gerstein H, Lonn E, Jacobs R, Vuksan V, et al Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation. 2003;108:420–425
  9. Koren-Morag N, Goldbourt U, Tanne D. Relation between the metabolic syndrome and ischemic stroke or transient ischemic attack: a prospective cohort study in patients with atherosclerotic cardiovascular disease. Stroke. 2005;36:1366–1371
  10. McGirt MJ, Woodworth GF, Brooke BS, Coon AL, Jain S, Buck D, et al. Hyperglycemia independently increases the risk of perioperative stroke, myocardial infarction, and death after carotid endarterectomy. Neurosurgery. 2006;58:1066–1072discussion 1073
  11. Echahidi N, Mohty D, Pibarot P, Després JP, O'Hara G, Champagne J, et al. Obesity and metabolic syndrome are independent risk factors for atrial fibrillation after coronary artery bypass graft surgery. Circulation. 2007;116(11 Suppl):I213–I219
  12. Theron JG, Payelle GG, Coskun O, Huet HF, Guimaraens L. Carotid artery stenosis: treatment with protected balloon angioplasty and stent placement. Radiology. 1996;201:627–636
  13. Alberti KG, Zimmet P, Shaw J IDF Epidemiology Task Force Consensus Group. The metabolic syndrome–a new worldwide definition. Lancet. 2005;366:1059–1062
  14. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–2752
  15. Yadav JS, Wholey MH, Kuntz RE, Fayad P, Katzen BT, Mishkel GJ, et al. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med. 2004;351:1493–1501
  16. Baker JD, Rutherford RB, Bernstein EF, Courbier R, Ernst CB, Kempczinski RF, et al. Suggested standards for reports dealing with cerebrovascular disease: Subcommittee on Reporting Standards for Cerebrovascular Disease, Ad Hoc Committee on Reporting Standards, Society for Vascular Surgery/North American Chapter, International Society for Cardiovascular Surgery. J Vasc Surg. 1988;8:721–729
  17. Gorter PM, Olijhoek JK, van der Graaf Y, Algra A, Rabelink TJ, Visseren FL SMART Study Group. Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Atherosclerosis. 2004;173:363–369
  18. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C, et al. American Heart Assoc Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433–438
  19. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003;9:237–252
  20. Bloomgarden ZT. Definitions of the insulin resistance syndrome: the 1st World Congress on the Insulin Resistance Syndrome. Diabetes Care. 2004;27:824–830
  21. Executive Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholestexrol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  22. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–2752
  23. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. http://www.diabetes.com.au/pdf/who_report.pdfAccessed on May 14, 2008
  24. Lev-Ran A. Human obesity: an evolutionary approach to understanding our bulging waistline. Diabetes Metab Res Rev. 2001;17:347–362
  25. Winter Y, Rohrmann S, Linseisen J, Lanczik O, Ringleb PA, Hebebrand J, et al. Contribution of obesity and abdominal fat mass to risk of stroke and transient ischemic attacks. Stroke. 2008;39:3145–3151
  26. Rockman CB, Saltzberg SS, Maldonado TS, Adelman MA, Cayne NS, Lamparello PJ, et al. The safety of carotid endarterectomy in diabetic patients: clinical predictors of adverse outcome. J Vasc Surg. 2005;42:878–883
  27. Ballotta E, Da Giau G, Renon L. Is diabetes mellitus a risk factor for carotid endarterectomy? (A prospective study). Surgery. 2001;129:146–152
  28. Kahn SE, Haffner SM, Iese MA, Herman WH, Colman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427–2443
  29. Romera C, Hurtado O, Mallolas J, Pereira MP, Morales JR, Romera A, et al. Ischemic preconditioning reveals that GLT1/EAAT2 glutamate transporter is a novel PPARgamma target gene involved in neuroprotection. J Cereb Blood Flow Metab. 2007;27:1327–1338
  30. Shimazu T, Inoue I, Araki N, Asano Y, Sawada M, Furuya D, et al. A peroxisome proliferator-activated receptor-gamma agonist reduces infarct size in transient but not in permanent ischemia. Stroke. 2005;36:353–359
  31. Sundarajan S, Gamboa JL, Victor NA, Wanderi EW, Lust WD, Landreth GE. Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience. 2005;130:685–696
  32. Pereira MP, Hurtado O, Cárdenas A, Boscá L, Castillo J, Dávalos A, et al. Rosiglitazone and 15-deoxy-delta 12,14-prostaglandin J2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms. J Cereb Blood Flow Metab. 2006;26:218–229

 Competition of interest: none.

 Additional material for this article may be found online at www.jvascsurg.org.

PII: S0741-5214(08)02154-X

doi: 10.1016/j.jvs.2008.12.011

Journal of Vascular Surgery
Volume 49, Issue 5 , Pages 1172-1180.e1 , May 2009

Article Tools

* Image Usage & Resolution